Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (3258)	3/23/2021 2:02:02 PM
From: Biotechwantabe	Read Replies (1) \| Respond to of 3557

Dose-ranging Virology Trial A companion dose-ranging Phase 2 trial of 803 outpatient COVID-19 patients was conducted to evaluate the antiviral effect of several different REGEN-COV doses (IV: 2,400 mg, 1,200 mg, 600 mg and 300 mg; SC: 1,200 mg and 600 mg). All tested doses met the primary endpoint, rapidly and significantly reducing patients' viral load (log10 copies/mL) compared to placebo (p£0.001). Each dose demonstrated similar efficacy, including the lowest doses tested (IV: 300 mg; SC: 600 mg). SC works at lowest 600mg dose. Ya, more clinical test required; but checkmate is coming soon enough. Lower doses may lead to additional revenue?

To: DewDiligence_on_SI who wrote (3258)	3/23/2021 4:01:45 PM
From: A.J. Mullen	Read Replies (1) \| Respond to of 3557

REGN needs to develop a subcutaneous formulation. How difficult is that? Presumably it's easier at lower doses. Might the threshold of possibility lie between 300 and 1200mg? Pfizer's starting a Phase I trial of a pill to block viral replication in people with the first symptoms of Covid, bloomberg.com. It should be much quicker for REGN to gain approval for modified delivery.